阿达木单抗治疗幼年特发性关节炎相关葡萄膜炎:SYCAMORE试验布里斯托尔参与者的5年随访
该回顾性干预性病例系列纳入SYCAMORE试验中布里斯托尔眼科医院招募的全部28例幼年特发性关节炎相关葡萄膜炎(JIA-U)患儿,随访至随机化后约5年。停用研究药物后,28例中25例因活动性JIA-U开始阿达木单抗;SYCAMORE试验活性治疗组12例中11例(92%)在停药后因活动性JIA-U重新启用阿达木单抗,中位复发时间188天(范围42-413天)。结论为阿达木单抗治疗1-2年后撤药,药物诱导的JIA-U缓解未能持续,阿达木单抗耐受性良好且视力结局优异。
要点
- 停用研究药物后,28例中25例因活动性JIA-U开始阿达木单抗。
- SYCAMORE活性治疗组12例中11例(92%)停药后重新启用阿达木单抗,中位复发时间188天。
- 2例因JIA-U未控制停用阿达木单抗,1例因白内障视力降至0.3。
核心结论
- 阿达木单抗治疗1-2年后撤药,药物诱导的JIA-U缓解未能持续。
- 阿达木单抗耐受性良好,视力结局优异。
研究设计与样本
- 回顾性干预性病例系列,纳入SYCAMORE试验中布里斯托尔眼科医院招募的全部28例JIA-U参与者,随访至随机化后约5年。
主要发现
- 停用研究药物后,28例中25例因活动性JIA-U开始阿达木单抗。
- SYCAMORE活性治疗组12例中11例(92%)在停用研究药物后因活动性JIA-U重新启用阿达木单抗,中位复发时间188天(范围42-413天)。
- 2例因JIA-U未控制停用阿达木单抗。
- 1例因白内障视力降至0.3。
- 其余27例平均视力为右眼-0.04、左眼-0.05。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine longer-term outcomes of participants enrolled from a single center in the SYCAMORE trial, a randomized placebo-controlled trial of adalimumab vs placebo in children with juvenile idiopathic arthritis-associated uveitis (JIA-U) uncontrolled on methotrexate. DESIGN: Retrospective interventional case series. METHODS: Medical records of all 28 SYCAMORE participants recruited at the Bristol Eye Hospital were reviewed at approximately 3-monthly intervals up to 5 years from the trial randomization date. Uveitis activity, treatment course, visual outcomes, ocular complications, and adverse events were recorded. Data are presented using summary statistics. RESULTS: Following withdrawal of the investigational medicinal product (IMP), 25 of the 28 participants were started on adalimumab for active JIA-U. Of the 12 participants in the active treatment arm of the SYCAMORE study, 11 (92%) were restarted on adalimumab after withdrawal of the IMP for active JIA-U (median time to flare 188 days [range 42-413 days). Two participants stopped adalimumab for uncontrolled JIA-U. One participant had a reduction in vision to 0.3 owing to cataract. Mean visual acuity for the remaining 27 participants was -0.04 (right eye) and -0.05 (left eye). CONCLUSIONS: Drug-induced remission of JIA-U did not persist when adalimumab was withdrawn after 1-2 years of treatment. Adalimumab was well tolerated and visual acuity outcomes were excellent.
引用
- Horton S, Jones AP, Guly CM, et al. Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial. Am J Ophthalmol. 2019. PMID: 31201796. doi:10.1016/j.ajo.2019.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。